Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR

Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of... Bioorganic & Medicinal Chemistry Letters 29 (2019) 631–637 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR a,1 a a a a a Wonken Choung , Hui Jin Jung , Deokmo Yang , Eun Hye Nam , Hyukjoon Choi , Bo Ram Lee , a a a a b b Min Park , Su Min Jang , Jae Soo Lim , Woo Sik Kim , Kyung-Hee Kim , Jungwook Chin , b b b b a Kyungjin Jung , Geumwoo Lee , Eunmi Hong , Tae-ho Jang , Jayhyuk Myung , a, ,1 Seong Heon Kim Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea ARTICLE INFO ABSTRACT Keywords: The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Drug discovery Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crys- Antidiabetics tallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding character- PPARgamma agonist istics versus traditional TZD full http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bioorganic & Medicinal Chemistry Letters Elsevier

Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR

Loading next page...
 
/lp/elsevier/identification-of-br101549-as-a-lead-candidate-of-non-tzd-ppar-agonist-NIqWfkcoRK
Publisher
Elsevier
Copyright
Copyright © 2018 Elsevier Ltd
ISSN
0960-894x
D.O.I.
10.1016/j.bmcl.2018.12.043
Publisher site
See Article on Publisher Site

Abstract

Bioorganic & Medicinal Chemistry Letters 29 (2019) 631–637 Contents lists available at ScienceDirect Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR a,1 a a a a a Wonken Choung , Hui Jin Jung , Deokmo Yang , Eun Hye Nam , Hyukjoon Choi , Bo Ram Lee , a a a a b b Min Park , Su Min Jang , Jae Soo Lim , Woo Sik Kim , Kyung-Hee Kim , Jungwook Chin , b b b b a Kyungjin Jung , Geumwoo Lee , Eunmi Hong , Tae-ho Jang , Jayhyuk Myung , a, ,1 Seong Heon Kim Research Center, Boryung Pharmaceuticals Co. Ltd., Republic of Korea New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF), Republic of Korea ARTICLE INFO ABSTRACT Keywords: The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Drug discovery Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crys- Antidiabetics tallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding character- PPARgamma agonist istics versus traditional TZD full

Journal

Bioorganic & Medicinal Chemistry LettersElsevier

Published: Feb 15, 2019

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off